

Capital Increase Report Form
E for L Aim Public Company Limited

December 9, 2020

We, E for L Aim Public Company Limited (the "Company"), hereby informs the resolutions of the Board of Directors Meeting No. 15/2020, held on December 9, 2020 between 12.00 a.m. and 3.00 p.m., regarding a capital increase and allocation of newly issued ordinary shares as follows.

1. Capital Increase

The Board of Directors passed a resolution to the Extraordinary General Shareholder Meeting No. 1/2021 to consider and approve for the following:

1.1 To decrease of the Company's registered capital of Baht 765,052,653.075 from the existing registered capital of Baht 3,181,554,810.300 to Baht 2,416,502,157.225 by cancelling ordinary shares of 10,200,702,041 shares with par value of Baht 0.075 per share;

1.2 To increase of the Company's registered capital from Baht 2,416,502,157.225 to Baht 2,998,398,708.975, by issuing 7,758,620,690 new ordinary shares with a par value of 0.075 Bath each, totaling Baht 581,896,551.750. Details of each type of capital increase are;

Type of Capital Increase	Type of shares	Number of shares	Par value (Baht/share)	Total (Baht)
<input checked="" type="checkbox"/> Specifying purpose of utilizing proceeds	Ordinary	<u>Less than</u> <u>7,758,620,690</u>	<u>0.075</u>	<u>581,896,551.750</u>
<input type="checkbox"/> General Mandate	Ordinary			

2. Allotment of new shares

2.1 Specifying purpose of utilizing proceeds

Allotted to	Number of shares	Ratio (Old : New)	Issuing Price (Baht/share) ^{2/}	Subscription and payment period ^{3/}	Remark
Private Placement ^{1/}				See note 3/	-
Mrs. Pimphen Deephanphong	5,747,126,437	-	Baht 0.0348		
Mr. Rerkchai Fooprateepsiri	1,436,781,609		Baht 0.0348		
Mrs. Pinpinut Yannakomthanapunt	574,712,644		Baht 0.0348		

Note

- 1/ The lists of private placement are disclosed in Information Memorandum of the Company, regarding a capital increase and allocation of newly issued ordinary shares to private placement.
- 2/ The pricing method is the specified offering price at 0.0348 Baht per share which is higher than 90 percent of the market price, according to the Notification of the Capital Market Supervisory Board No. Tor Jor 72/2015, regarding the listing of newly issued shares to private placement.
- 3/ The date and time for subscription and payment period shall be announced later by the Board of Directors and/or the Chief Executive Officer and/or the authorized person from the Board of Directors and/or the authorized person from the Chief Executive Officer entrusted with the power to determine the conditions and details relating to the financing of capital increase to private placement, including the power to (1) Determination and amendment of the subscription date and the offering date of the newly issued ordinary shares, allocation of newly issued ordinary shares at once or occasionally, stock payment including conditions and other details relating to the subscription and offering of the newly issued ordinary shares. If the offering shares incur after 3rd months after getting the approval from shareholders, the increased shares must be offered at the market price (the market price means the weighted average price of the Company's shares traded on the Stock Exchange during 15 working days prior to the offering date) (2) negotiating and signing the documents and contracts relating to the issuance and capital increase to private placement (3) signing the documents in the application and the related necessary documents relation to the offered shares to private placement including to coordinate and submit any permission documentation to SET/SEC or related departments (4) listing the new ordinary shares on the SET and (5) any other action necessary related to the issuance of new ordinary shares to the private placement. Nonetheless, on the offering date, if the offering price is less than 90 percent of the market price (calculated from the weighted average price of the Company's shares traded on the Stock Exchange during 7-15 working days prior to the offering date), the investors above will be banned from trading the allocated newly issued ordinary shares within 1 year from the date that such shares are listed by SET (Listing Date). After 6 months of the allocated date, the investor can sell their shares in the amount of 25 percent of the total number of shares prohibited for sale.

3. Schedule for a shareholders' meeting to approve the capital increase and the allocation of shares

The Extraordinary General Meeting of shareholders No.1/2021 is scheduled to be held on February 9, 2021 at 9.30 a.m., through Electronic Meeting (E-Meeting) by arranging live broadcast the E-Meeting from the meeting room on 6th floor, Ngamwongwan Road, Bangkhen, Mueang, Nonthaburi District, Nonthaburi.

The closing date of share register book for the right to attend a shareholder meeting will be started on.....until the shareholder meeting is completed.

To specification the Record Date for the right to attend the meeting on December 28, 2020.

4. Approval of the capital increase and the allocation or allotment by relevant governmental agency and conditions thereto (if any)

- 4.1 The Company is required to seek an approval from the Shareholders Meeting with the vote of not less than three-fourth of the total number of votes of the shareholders attending the meeting and having the right to vote.
- 4.2 The Company will submit the application to the SEC for approval on the private placement of shares.
- 4.3 The Company will register the increase of the registered capital and paid-up capital with the Department of Business Development, the Ministry of Commerce.

4.4 The Company will submit the application to the SET for listing of the newly issued ordinary shares.

5. Objectives of the capital increase and plans for utilizing proceeds received from the capital increase

The Company needs to seek funding to increase liquidity and working capital for medical device business due to credit facility of the Company is limited by the policy of the financial institution. It is expected to utilise the funding of Baht 270 million for increase liquidity and working capital within the third quarter of 2021.

6. Benefits which the Company will receive from the capital increase and share allotment

To have sufficient funding to purchase products from overseas and to serve the strengthen the Company's financial status for demand of medical devices under Covid-19 situations. In addition, some investor has its business related with the Company and some investor has knowledge and capability which may share knowledge to develop the Company's product which will increase the Company's potential for its future expansion.

7. Benefits which shareholders will receive from the capital increase and share allotment

7.1. Improve the Company's financial status and the Company's creditability to suppliers and shareholders.

7.2. The Company shall have sufficient funding to get the credit facility from the financial institutions and partners which will be able to serve customer requirement. These will generate more revenue resulting in getting the better operating performance.

8. Other details necessary for shareholders to approve the capital increase and share allotment

Please consider the details in Information Memorandum of the Company, regarding a capital increase and allocation of newly issued ordinary shares to private placement.

9. Schedule of actions if the board of directors passes a resolution approving the capital increase or allotment of new shares

No.	Process	Date
9.1	The Board of Directors Meeting No. 15/2020	December 9, 2020
9.2	Record Date for the right to attend the Extraordinary General Meeting of Shareholders no. 1/2021	December 28, 2020
9.3	The Extraordinary General of Meeting of the Shareholders No.1/2021	February 9, 2021
9.4	Registration of the increase of registered capital and amendment to the relevant Memorandum of Association with the Ministry of Commerce	Within 14 days from the Extraordinary General of Meeting of the Shareholders No. 1/2021
9.5	Subscription and payment period for the private placement	After receiving approval from the SEC

The Company hereby certifies that the information contained in this report form is true and complete in all respects.

..... Authorized Person

(Mr. Preecha Nuntnarumit)

..... Authorized Person

(Mr. Jackrit Lohajaroensub)